Recent Post
Related Posts
POTOMAC, MARYLAND, September 9, 2025 – IGC Pharma, Inc. (NYSE American: IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer’s disease, today announced that its Artificial Intelligence (AI) team
IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada
POTOMAC, MD, September 02, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in
POTOMAC, MARYLAND, August 28, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
POTOMAC, MARYLAND, August 27, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: “Reports Q1 results. We believe more positive
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
POTOMAC, MD, August 25, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating